Efficacy and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Measure Up 1, Measure Up 2, and AD Up Phase 3 Clinical Trials at 52 Weeks

被引：0

作者：

Paller, Amy ^{[1
]}

Mendes-Bastos, Pedro ^{[2
]}

Eichenfield, Lawrence ^{[3
,4
,5
]}

Soong, Weily ^{[6
]}

Lio, Peter ^{[7
]}

Prajapati, Vimal ^{[8
,9
,10
]}

Platt, Andrew ^{[11
]}

Liu, John ^{[11
]}

Ladizinski, Barry ^{[11
]}

Thyssen, Jacob

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA

[2] Hosp CUF Descobertas, Dermatol Ctr, Lisbon, Portugal

[3] Univ Calif San Diego, Sch Med, Rady Childrens Hosp, Div Pediat & Adolescent Dermatol, San Diego, CA USA

[4] Univ Calif San Diego, Sch Med, Dept Dermatol, San Diego, CA USA

[5] Univ Calif San Diego, Sch Med, Dept Pediat, San Diego, CA USA

[6] AllerVie HealthAlabama Allergy & Asthma Ctr & Cli, Birmingham, AL USA

[7] Med Dermatol Associates Chicago, Chicago, IL USA

[8] Univ Calgary, Div Dermatol, Dept Med, Calgary, AB, Canada

[9] Univ Calgary, Sect Community Pediat, Dept Pediat, Calgary, AB, Canada

[10] Univ Calgary, Sect Pediat Rheumatol, Calgary, AB, Canada

[11] AbbVie Inc, N Chicago, IL USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

43049

引用

页码：AB157 / AB157

页数：1

共 50 条

[21] Achieving incrementally greater skin improvement thresholds with upadacitinib in moderate-to-severe atopic dermatitis: a pooled analysis of two phase III studies (Measure Up 1 and Measure Up 2)
Reich, K.
Langley, R. G.
Calimlim, B. M.
Teixeira, H. D.
Zeng, J.
Silverberg, J. I.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E131 - E132
[22] Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from two pivotal, phase III, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2)
Guttman-Yassky, E.
Teixeira, H. D.
Simpson, E. L.
Papp, K. A.
Pangan, A. L.
Blauvelt, A.
Thaci, D.
Chu, C. Y.
Hong, H. C.
Katoh, N.
Paller, A. S.
Calimlim, B.
Gu, Y.
Hu, X.
Liu, M.
Yang, Y.
Tenorio, A. R.
Chu, A. D.
Irvine, A. D.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E62 - E62
[23] Characterization of hematologic and transaminase laboratory findings associated with upadacitinib in moderate-to-severe atopic dermatitis: Results of two phase 3 trials (measure up 1 and 2)
Silverberg, Jonathan I.
Gooderham, Melinda J.
de Bruin-Weller, Marjolein S.
Papp, Kim A.
Aoki, Valeria
Paller, Amy S.
Ofori, Sarah
Tenorio, Allan R.
Liu, Yingyi
Liu, Jianzhong
Chovatiya, Raj
CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1010 - 1010
[24] Improvement in Itch, Symptoms, and Quality of Life With Upadacitinib Through Week 16 in Adults and Adolescents With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
Lio, Peter
Eichenfield, Lawrence F.
Marcoux, Danielle
Lee, Wan-Ju
Teixeira, Henrique D.
Raymundo, Eliza M.
Gamelli, Amy E.
Grada, Ayman
Hu, Xiaofei
Irvine, Alan D.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB178 - AB178
[25] UPADACITINIB VERSUS DUPILUMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF THE HEADS UP PHASE 3 TRIAL
Blauvelt, Andrew
Teixeira, Henrique D.
Simpson, Eric L.
Costanzo, Antonio
De Bruin-Weller, Marjolein
Barbarot, Sebastien
Prajapati, Vimal H.
Lio, Peter
Hu, Xiaofei
Wu, Tianshuang
Liu, John
Ladizinski, Barry
Chu, Alvina D.
Eyerich, Kilian
ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 62 - 62
[26] Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results
Silverberg, Jonathan, I
Guttman-Yassky, Emma
Simpson, Eric L.
Papp, Kim A.
Blauvelt, Andrew
Chu, Chia-Yu
Hong, H. Chih-ho
Gold, Linda F. Stein
Bieber, Thomas
Kabashima, Kenji
Rosmarin, David
Gamelli, Amy
Calimlim, Brian
Vigna, Namita
Hu, Xiaofei
Yang, Yang
Wu, Xiaoqiang
Huang, Xiaohong
Suravaram, Smitha
Teixeira, Henrique D.
Raymundo, Eliza
Irvine, Alan D.
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II8 - II8
[27] 413 Improvement in itch, symptoms and quality of life with upadacitinib through week 16 in adults and adolescents with atopic dermatitis: results from phase 3 studies (Measure Up 1, Measure Up 2 and AD Up)
Lio, Peter
Eichenfield, Lawrence F.
Marcoux, Danielle
Lee, Wan-Ju
Teixeira, Henrique D.
Raymundo, Eliza M.
Gamelli, Amy E.
Grada, Ayman
Hu, Xiaofei
Irvine, Alan D.
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[28] Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
Silverberg, Jonathan I.
Deleuran, Mette
Gold, Linda S.
Bunick, Christopher G.
Hijnen, Dirk Jan
Calimlim, Brian M.
Teixeira, Henrique D.
Platt, Andrew M.
Grada, Ayman
Hu, Xiaofei
Gooderham, Melinda
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB90 - AB90
[29] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
Herranz, Pedro
de la Cueva, Pablo
Rodriguez Marco, Ainara
Worrell, Richard
Shumel, Brad
INTERNAL MEDICINE JOURNAL, 2021, 51 : 25 - 25
[30] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
Roh, Joo Young
Park, Chun Wook
Kim, Kyu Han
Lee, Joo Hee
Sun, Xian
Rossi, Ana B.
Shumel, Brad
ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 53 - 53

← 1 2 3 4 5 →